Drug General Information (ID: DDIRPQSXC3)
Drug Name			Ipilimumab		Drug Info		Desirudin		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Anticoagulants

Mechanism of Ipilimumab-Desirudin Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ipilimumab				Desirudin
Mechanism		Risk of bleeding Antiplatelet/anticoagulant effects				Risk of bleeding Anticoagulant
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Ipilimumab and Desirudin

Recommended Action
Management		If anticoagulant treatment is required, caution and close monitoring for gastrointestinal bleeding is advisable.

References
1	Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."